We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 25, 2021

Molecular Response and Quality of Life in CML Patients Treated With Intermittent TKIs

Cancer Medicine


Additional Info

Cancer Medicine
Molecular Response and Quality of Life in Chronic Myeloid Leukemia Patients Treated With Intermittent TKIs: First Interim Analysis of OPTkIMA Study
Cancer Med 2021 Feb 16;[EPub Ahead of Print], M Malagola, A Iurlo, E Abruzzese, M Bonifacio, F Stagno, G Binotto, M D'Adda, M Lunghi, M Crugnola, ML Ferrari, F Lunghi, F Castagnetti, G Rosti, RM Lemoli, R Sancetta, MR Coppi, MT Corsetti, G Rege Cambrin, A Romano, M Tiribelli, A Russo Rossi, S Russo, L Aprile, L Gandolfi, M Farina, S Bernardi, N Polverelli, AM Roccaro, A De Vivo, M Baccarani, D Russo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading